다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
La Revue de médecine interne, v.42 no.2, 2021년, pp.93 - 100
Tazi Mezalek, Z. (Service mé)
AI-Helper
Abstract The SARS-CoV-2 virus caused a global pandemic within weeks. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe...
Résumé Le virus SARS-CoV-2 a provoqué une pandémie mondiale en quelques semaines, causant l’infection de plus de 20 millions de sujets. Près du 15 % des patients atteints de la maladie à coronavirus 2019 (COVID-19) et plus de 70 % des formes graves présentent des anomalies de coagulation. Cet état « d’hypercoagulabilité » incluant essentiellement une élévation marquée des D-Dimères est associé à un risque accru de décès. En outre, une proportion substantielle de patients atteints de COVID-19 sévère développent des complications thromboemboliques veineuses, incidence d’autant plus élevée que les patients sont admis en unités de soins intensifs ou en réanimation. Une meilleure compréhension de la physiopathologie de la COVID-19, en particulier des troubles de l’hémostase, permettra d’adapter des stratégies thérapeutiques, notamment anti-thrombotiques. La mise en évidence de ces anomalies doit être associée à une évaluation rigoureuse du risque thrombotique permettant la mise en place d’une stratégie anti-thrombotique adaptée. Nous passons en revue les caractéristiques des données biologiques de la « coagulopathie » associée à la COVID-19, l’incidence des événements thromboemboliques et leurs spécificités ainsi que les interventions thérapeutiques potentielles.
1 Ren L.L. Wang Y.M. Wu Z.Q. Xiang Z.C. Guo L. Xu T. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study Chin Med J 133 9 2020 1015 1024 32004165
2 World Health Organization Coronavirus Disease 2019 (COVID-19) situation report 2004 [https://www.who.int/docs/default-source/coronaviruse/situationreports/20200306-sitrep-46-covid-19pdf?sfvrsn¼96b04adf_2]
3 Wu Z. Mc Googan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID 19) outbreak in china summary of a report of 72.314？cases from the Chinese center for disease control and prevention JAMA 323 13 2020 1239 1242 32091533
4 Onder G. Rezza G. Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19？in Italy JAMA 323 18 2020 1775 1776 32203977
5 Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. Clinical features of patients infected with 2019？novel coronavirus in Wuhan China. Lancet 395 10223 2020 497 506 31986264
6 Chen T. Wu D. Chen H. Yan W. Yang D. Chen G. Clinical characteristics of 113？deceased patients with coronavirus disease 2019: retrospective study BMJ 368 2020 m1091 32217556
7 Zhou F. Yu T. Du R. Fan G. Liu Y. Liu Z. Clinical course and risk factors for mortality of adult in patients with COVID-19？in Wuhan, China: a retrospective cohort study Lancet 395 10229 2020 1054 1062 32171076
8 Tang N. Li D. Wang X. Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia J Thromb Haemost 18 4 2020 844 847 32073213
9 Wu C. Chen X. Cai Y. Xia J. Zhou X. Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019？pneumonia in Wuhan, China JAMA Intern Med 180 7 2020 1 11
10 Fogarty H. Townsend L. Ni Cheallaigh C. Bergin C. Martin-Loeches I. Browne P. COVID-19？coagulopathy in Caucasian patients Br J Hematol 189 6 2020 1060 1061
11 Han H. Yang L. Liu R. Liu F. Wu K.L. Li J. Prominent changes in blood coagulation of patients with SARS-CoV-2？infection Clin Chem Lab Med 58 7 2020 1116 1120 32172226
12 Levi M. Toh C.H. Thachil J. Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation Br J Haematol 145 1 2009 24 33 19222477
13 Khider L. Gendron N. Goudot G. Chocron R. Hauw-Berlemont C. Cheng C. Curative anticoagulation prevents endothelial lesion in COVID-19？patients J Thromb Haemost 18 9 2020 2391 2399 32558198
14 Sakka M. Connors J.M. Hekimian G. Martin-Toutain I. Crichi B. Colmegna I. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis J Med Vas 45 5 2020 268 274
15 Rauch A. Labreuche J. Lassalle F. Goutay J. Caplan M. Charbonnier L. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19 J Thromb Haemost 18 11 2020 2942 2953 32881304
16 Feng Y. Ling Y. Bai T. Xie Y. Huang J. Li J. COVID-19？with different severity: a multi-center study of clinical features Am J Resp Crit Care Med 201 11 2020 1380 1388 32275452
17 Wang D. Hu B. Hu C. Zhu F. Liu X. Zhang J. Clinical characteristics of 138？hospitalized patients with 2019？novel coronavirus-infected pneumonia in Wuhan, China JAMA 323 11 2020 1061 1069 32031570
18 De Wit E. van Doremalen N. Falzarano D. Munster V.J. SARS and MERS: recent insights into emerging coronaviruses Nat Rev Microbiol 534 2 2016 523 534
19 Ng K.H. Wu A.K. Cheng V.C. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome Postgrad Med J 81 956 2005 e3 15937197
20 Liao S. Woulfe T. Hyder S. Merriman E. Simpson D. Chunilal S. Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study J Thromb Haemost 12 2 2014 214 219 24283769
21 Cui S. Chen S. Li X. Liu S. Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia J Thromb Haemost 18 6 2020 1421 1424 32271988
22 Ren B. Yan F. Deng Z. Zhang S. Xiao L. Wu M. Extremely high incidence of lower extremity deep venous thrombosis in 48？patients with severe COVID-19？in Wuhan Circulation 142 2 2020 181 183 32412320
23 Klok F.A. Kruip M.J.H.A. van der Meerc N.J.M. Arbous M.S. Gommers DAMPJ Kant K.M. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromb Res 191 2020 145 147 32291094
24 Middeldorp S. Coppens M. van Haaps T.F. Foopen M. Vlaar A.P. Muller M.C.A. Incidence of venous thromboembolism in hospitalized patients with COVID-19 J Thromb Haemost 18 8 2020 1995 2002 32369666
25 Helms J. Tacquard C. Severac F. Leonard-Lorent I. Ohana M. Delabranche X. High risk of thrombosis in patients in severe SARS-CoV-2？infection: a multicenter prospective cohort study J Int Care Med 46 6 2020 1089 1098
26 Poissy J. Goutay J. Caplan M. Parmentier E. Duburcq T. Lassalle F. Pulmonary embolism in COVID-19？patients: awareness of an increased prevalence Circulation 142 2 2020 184 186 32330083
27 Malato A. Dentali F. Siragusa S. Fabbiano F. Kagoma Y. Boddi M. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes Blood Transfus 13 4 2015 559 568 26513770
28 Leonard-Lorant I. Delabranche X. Severac F. Helms J. Pauzet C. Collange O. Acute pulmonary embolism in COVID-19？patients on CT angiography and relationship to D-Dimer levels Radiology 296 3 2020 E189 E191 32324102
29 Grillet F. Behr J. Calame P. Aubry S. Delabrousse E. Acute pulmonary embolism associated with COVID-19？pneumonia detected by pulmonary CT angiography Radiology 296 3 2020 E186 E188 32324103
30 Poyiadi N. Cormier P. Patel P.Y. Hadied M.O. Bhargava P. Khanna K. Acute pulmonary embolism and COVID-19 Radiology 297 3 2020 E335 E338 32407256
31 Klok F.A. Kruipb M.J.H.A. van der Meerc N.J.M. Arbous M.S. Gommers D. Kant K.M. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Thromb Res 191 2020 148 150 32381264
32 Thomas W. Varley J. Johnston A. Symington E. Robinson M. Sheares K. Thrombotic complications of patients admitted to intensive care with COVID-19？at a teaching hospital in the United Kingdom Thromb Res 191 2020 76 77 32402996
33 Llitjos J.F. Leclerc M. Chochois C. Monsallier J.M. Ramakers M. Auvray M. High incidence of venous thromboembolic events in anticoagulated severe COVID-19？patients J Thromb Haemost 18 7 2020 1743 1746 32320517
34 Voicu S. Bonnin P. Stepanian A. Chousterman B.G. Le Gall A. Malissin I. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19？patients J Am Coll Cardiol 76 4 2020 15
35 Lodigiani C. Iapichino G. Carenzo L. Venous and arterial thromboembolic complications in COVID-19？patients admitted to an academic hospital in Milan, Italy Thromb Res 191 2020 9 14 32353746
36 Demelo-Rodriguez P. Cervilla-Munoz E. Ordieres-Ortega L. Parra-Virto A. Toledano-Macias M. Toledo-Samaniego N. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19？pneumonia and elevated D-Dimer levels Thromb Res 192 2020 23 26 32405101
37 Zhang L. Feng X. Zhang D. Jiang C. Mei H. Wang J. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome Circulation 142 2 2020 114 128 32421381
38 Fox S.E. Akmatbekov A. Harbert J.L. Li G. Quincy Brown J. Vander Heide R.S. Pulmonary and cardiac pathology in African American with COVID-19: an autopsy series from New Orleans Lancet Respir Med 8 7 2020 681 686 32473124
39 Wichmann D. Sperhake J.P. Lutgehetmann M. Steurer S. Edler C. Heinemann A. Autopsy findings and venous thromboembolism in patients with COVID-19. a prospective cohort study Ann Int Med 173 4 2020 268 277 32374815
40 Menter T. Haslbauer J.D. Nienhold R. Savic S. Hopfer H. Deigendesch N. Post-mortem examination of COVID19？patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Histopathology 77 2020 198 209 32364264
41 Lax S.F. Skok K. Zechner P. Kessler H.H. Kaufmann N. Koelblinger C. Pulmonary arterial thrombosis in COVID-19？with fatal outcome: results from a prospective, single-center, clinicopathologic case series Ann Int Med 173 5 2020 350 361 32422076
42 Cattaneo M. Bertinato E.M. Birocchi S. Pulmonary embolism or pulmonary thrombosis in COVID-19?. is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost 120 8 2020 1230 1232 32349132
43 Palareti G. Antonucci E. Dentali F. Mastroiacovo D. Mumoli N. Pengo V. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution Eur J Intern Med 69 2019 64 70 31500936
44 Marongiu F. Mameli A. Grandone E. Barcellona D. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism? Semin Thromb Hemost 45 8 2019 778 783 31537029
45 Saba L. Sverzellati N. Is COVID evolution due to occurrence of pulmonary vascular thrombosis? J Thorac Image 2020 10.1097/RTI.0000000000000530
46 Panigada M. Bottino N. Tagliabue P. Grasselli G. Novembrino C. Chantarangkul V. Hypercoagulability of COVID-19？patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis J Thromb Haemost 18 7 2020 1738 1742 32302438
47 Ranucci M. Ballotta A. Di Dedda U. Bayshnikova E. Dei Poli M. Resta M. The procoagulant pattern of patients with COVID-19？acute respiratory distress syndrome J Thromb Haemost 18 7 2020 1747 1751 32302448
48 Connors J.M. Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19 J Thromb Haemost 18 7 2020 1559 1561 32302453
49 Ye Q. Wang B. Mao J. Cytokine storm in COVID-19？and treatment J Infection 80 6 2020 607 613
50 Jackson S.P. Darbousset R. Schoenwaelder S.M. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms Blood 133 9 2019 906 918 30642917
51 Monteil V. Kown H. Prado P. Hagelkruys A. Wimmer R.A. Stahl M. Inhibition of SARS-CoV-2？infections in engineered human tissues using clinical-grade soluble human ACE2 Cell 181 4 2020 905 913 32333836
52 Liu Z. Xiao X. Wei X. Li J. Yang J. Tan H. Composition and divergence of coronavirus spike proteins and host ACE2？receptors predict potential intermediate hosts of SARS-CoV-2 J Med Virol 92 6 2020 595 601 32100877
53 Varga Z. Flammer A.J. Steiger P. Haberecker M. Andermatt R. Zinkernagel A.S. Endothelial cell infection and endotheliitis in COVID-19 Lancet 395 10234 2020 1417 1418 32325026
54 Engelmann B. Massberg S. Thrombosis as an intravascular effect or of innate immunity Nat Rev Immunol 13 1 2013 34 45 23222502
55 Henry B.M. Vikse J. Benoit S. Favaloro E.J. Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hyper coagulopathy and microvascular immunothrombosis Clin Chim Acta 507 2 2020 167 173 32348783
56 Zhang Y. Xiao M. Zhang S. Xia P. Cao W. Jiang W. Coagulopathy and antiphospholipid antibodies in patients with Covid-19 N Engl J Med 382 17 2020 e38 32268022
57 Harzallah I. Debliquis A. Drenou B. Lupus anticoagulant is frequent in patients with Covid-19 J Thromb Haemost 18 8 2020 2064 2065 32324958
58 Joste V. Dragon-Durey M.A. Darnige L. Laboratory diagnosis of antiphospholipid syndrome Rev Med Interne 39 2018 34 41 28302338
59 Tang N. Bai H. Chen X. Gong J. Li D. Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019？patients with coagulopathy J Thromb Haemost 18 5 2020 1094 1099 32220112
60 Paranjpe I. Fuster V. Lala A. Russak A.J. Glicksberg B.S. Levin M.A. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 J Am Coll Cardiol 76 1 2020 122 124 32387623
61 Connors J.M. Levy J.H. COVID-19？and its implications for thrombosis and anticoagulation Blood 135 23 2020 2033 2040 32339221
62 Cohen A.T. Spiro T.E. Buller H.R. Haskell L. Hu D. Hull R. Rivaroxaban for thromboprophylaxis in acutely ill medical patients N Engl J Med 368 06 2013 513 523 23388003
63 Goldhaber S.Z. Leizorovicz A. Kakkar A.K. Haas S.K. Merli G. Knabb R.M. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients N Engl J Med 365 23 2011 2167 2177 22077144
64 Driggin E. Madhavan M.V. Bikdeli B. Chuich T. Laracy J. Biondi-Zoccai G. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic J Am Coll Cardiol 75 18 2020 2352 2371 32201335
65 Wang T. Chen R. Liu C. Liang W. Guan W. Tang R. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 Lancet Haematol 7 5 2020 e362 e363 32278361
66 Thachil J. Tang N. Gando S. Falanga A. Cattaneo M. Levi M. ISTH interim guidance on recognition and management of coagulopathy in COVID-19 J Thromb Haemost 18 5 2020 1023 1026 32338827
67 Bikdeli B. Madhavan M.V. Jimenez D. Chuich T. Dreyfus I. Driggin E. COVID-19？and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the art review J Am Coll Cardiol 75 23 2020 2950 2973 32311448
68 Song J.C. Wang G. Zhang W. Zhang Y. Li W.Q. Zhou Z. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 Mil Med Res 7 1 2020 19 32307014
69 Oudkerk M. Buller H.R. Kuijpers D. van Es N. Oudkerk S.F. McLoud T. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the national institute for public health of the Netherlands Radiology 297 1 2020 E216 E222 32324101
70 Moores L.K. Tritschler T. Brosnahan S. Carrier M. Collen J.F. Doerschug K. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: chest guideline and expert panel report Chest 158 3 2020 1143 1163 32502594
71 Spyropoulos A.C. Levy J.H. Ageno W. Connors J.M. Hunt B.J. Iba T. Scientific and standardization committee communication: clinical guidance on the diagnosis. Prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19 J Thromb Hemost 18 8 2020 1859 1865
72 Barbar S. Noventa F. Rossetto V. Ferrari A. Brandolin B. Perlati M. Risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score J Thromb Haemost 8 2010 24 50
73 Spyropoulos A.C. Anderson F.A. Jr. FitzGerald G. Decousus H. Pini M. Chong B.H. Predictive and associative models to identify hospitalized medical patients at risk for VTE Chest 140 3 2011 706 714 21436241
74 Simonnet A. Chetboun M. Poissy J. Raverdy V. Noulette J. Duhamel A. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation Obesity 28 7 2020 1195 1199 32271993
75 Kahn S.R. Lim W. Dunn A.S. Cushman M. Dentali F. AklEA, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2？suppl 2012 e195S-e226S
76 Schunemann H.J. Cushman M. Burnett A.E. Kahn S.R. Beyer-Westendorf J. Spencer F.A. American Society of Hematology 2018？guidelines for management of venous thromboembolism: prophylaxis for hospitalized and non hospitalized medical patients Blood Adv 2 2018 3198 3225 30482763
77 Susen S. Tacquard C.A. Godon A. Mansour A. Garrigue D. Nguyen P. Prevention of thrombotic risk in hospitalized patients with COVID-19？and hemostasis monitoring Crit Care 24 1 2020 364 32560658
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.